Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Cardiogen

AEDR, H-Ala-Glu-Asp-Arg-OH

A synthetic tetrapeptide bioregulator that may support cardiac tissue repair, fibroblast activity, and exhibit anti-tumor effects in research settings.

Quick Stats
Studies 54
Trials 4
Formula C18H31N7O9
Clear All
Utility 3
pubmed Jun 16, 2025

Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry.

Jobbé-Duval. Antoine A; Kharoubi. Mounira M; Donal. Erwan E; Bauer. Fabrice F; Broussier. Amaur...

In people over 80 with a rare heart disease called transthyretin amyloidosis, taking the drug tafamidis helped them live longer. After three years, about 57% of those on the medicine were still alive compared to 40% who didn’t get it. The benefit was seen even in patients older than 85, especially when the disease was caught early.

Utility 3
pubmed Feb 6, 2022

Prevalence and determinants of iron deficiency in cardiac amyloidosis.

Jobbé-Duval. Antoine A; Bézard. Mélanie M; Moutereau. Stéphane S; Kharoubi. Moun...

About half of people with cardiac amyloidosis have low iron, especially those with the ATTR forms, diabetes, or who take aspirin. Low iron didn’t change overall death rates, but the high prevalence suggests it’s worth checking and possibly treating.

Utility 2
pubmed Feb 14, 2024

Prevalence and phenotypes associated with ALPK3 null variants in a large French multicentric cohort: Confirming its involvement in hypertrophic cardiomyopathy.

Ader. Flavie F; Jedraszak. Guillaume G; Janin. Alexandre A; Billon. Clarisse C; Buisson. Nathalie Ro...

A big French study looked at people with loss‑of‑function changes in the ALPK3 gene. They found that kids with two bad copies get a severe form of hypertrophic cardiomyopathy (HCM) that can lead to heart failure or even need a transplant. Adults with just one bad copy also often develop HCM, sometimes with a specific pattern of heart thickening. The researchers suggest checking the ALPK3 gene when doctors see unexplained HCM.

Utility 2
pubmed Nov 20, 2025

Characteristics and Prognosis of Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Diagnosed Before 65 Years Old.

Guijarro. Damien D; Eicher. Jean-Christophe JC; Bézard. Mélanie M; Piriou. Nicolas N; Saue...

The study looked at people with a heart disease called wild‑type transthyretin amyloid cardiomyopathy (ATTRwt‑CM) who were diagnosed before age 65. It found that early‑diagnosed patients make up a small slice of all cases, tend to have more joint and bone problems, and are diagnosed much faster than older patients. Their survival after diagnosis is better than those diagnosed later.

Utility 2
pubmed Nov 9, 2020

Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.

Bézard. Mélanie M; Kharoubi. Mounira M; Galat. Arnault A; Poullot. Elsa E; Guendouz. Soule...

In a large French study of patients with transthyretin amyloidosis, taking the drug tafamidis was linked to almost double the time without major heart problems, heart transplants, or death compared to not taking it. This matches the benefits seen in earlier clinical trials and suggests the drug works well in everyday medical settings.

Utility 2
pubmed May 20, 2002

[Investigation of insertion/deletion polymorphism of the ACE gene in stroke patients].

Pongrácz. Endre E; Tordai. Attila A; Csornai. Márta M; Nagy. Zoltán Z

The study looked at a common genetic variation (I/D) in the ACE gene and its link to stroke. It found that having the D/D version of this gene alone doesn’t raise stroke risk, but in younger people who also have high cholesterol or high blood‑clotting proteins, the D/D version may make stroke more likely.

Utility 1
pubmed Sep 1, 2009

Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats.

Levdik. N V NV; Knyazkin. I V IV

In a study on older rats with a transplanted sarcoma, giving them the peptide called cardiogen made the tumors shrink. The peptide caused more tumor cells to die and triggered bleeding inside the tumor, but it didn't directly stop the cells from multiplying. The effect seemed to come from how the peptide affected the tumor's blood vessels.

Utility 1
pubmed Aug 10, 2024

Systematic analysis of SCN5A variants associated with inherited cardiac diseases.

Hermida. Alexis A; Jedraszak. Guillaume G; Ader. Flavie F; Denjoy. Isabelle I; Fressart. Véroni...

Most harmful changes in the SCN5A gene lead to heart rhythm problems like Brugada syndrome, while only a small share cause mixed or unclear heart issues, and it is very rare for these changes to cause dilated cardiomyopathy.

Utility 1
pubmed Oct 15, 2024

A series of cases of transthyretin amyloid cardiomyopathy with negative bone scintigraphy but a confirmed positive endomyocardial biopsy.

Fraix. Antoine A; Itti. Emmanuel E; Zaroui. Amira A; Kharoubi. Mounira M; Poullot. Elsa E; Lerman. L...

In a real‑world study of 271 people with confirmed transthyretin amyloid heart disease, about 5% showed no uptake on the usual bone‑scintigraphy scan, meaning the scan missed the disease. A repeat scan sometimes caught the problem, but in six cases the scan was completely negative and only a heart tissue biopsy gave the correct diagnosis.

Utility 1
pubmed May 27, 2025

Men and women differ with regard to the prevalence, phenotype, and prognosis of wild-type transthyretin amyloid cardiomyopathy.

Zaroui. Amira A; Lafont. Charlotte C; Kharoubi. Mounira M; Audureau. Etienne E; Bézard. Mé...

In a large French study of people with a heart disease called wild‑type transthyretin amyloid cardiomyopathy (ATTRwt‑CM), only 16% were women. Women tended to have a slightly better heart pumping ability but a thinner heart wall, and they were three times more likely to die suddenly than men. The study suggests that using a lower cut‑off for heart wall thickness could help diagnose more women earlier.

Utility 1
pubmed Jun 30, 2025

Diagnostic pathway for cardiac amyloidosis from the healthcare professional's perspective: results from the French DIAM-ATTR survey.

Oghina. Silvia S; Legallois. Damien D; Hyafil. Fabien F; Amara. Walid W; Andrès. Emmanuel E; Ba...

A French survey of doctors showed that diagnosing transthyretin cardiac amyloidosis is tricky: cardiologists are usually aware of it, but many other specialists often miss the signs. The typical diagnostic steps start with an echo, followed by blood tests for abnormal proteins and a bone scan, but there are delays and gaps in knowledge about the disease's warning signs.

Utility 1
pubmed Dec 7, 2021

Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region.

Schwartz. Peter J PJ; Moreno. Cristina C; Kotta. Maria-Christina MC; Pedrazzini. Matteo M; Crotti. L...

The study looked at a specific heart gene (KCNQ1) and found that a mutation called p.A341V makes people more likely to have dangerous heart rhythm problems, while nearby mutations also raise risk but not as much. The severity is linked to how these mutations affect the heart's electrical channel regulation.

Utility 1
pubmed May 6, 2020

Psychosocial Impact of Predictive Genetic Testing in Hereditary Heart Diseases: The PREDICT Study.

Bordet. Céline C; Brice. Sandrine S; Maupain. Carole C; Gandjbakhch. Estelle E; Isidor. Bertran...

The study looked at how people feel before and after getting genetic test results for inherited heart disease. Anxiety spikes before the test, drops back after the result, but stays a bit higher years later, especially in folks who already had depression or high anxiety. Most people didn't regret testing, but a noticeable minority saw negative changes at work or home.

Utility 1
pubmed Dec 22, 2020

Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis.

Kharoubi. Mounira M; Roche. Fréderic F; Bézard. Mélanie M; Hupin. David D; Silva. Sid...

In older people with a type of heart amyloidosis called ATTRwt-CA, about half show signs of autonomic nerve damage when measured with a quick skin test (Sudoscan). Those with lower test values tend to have worse heart outcomes and higher risk of death.

Utility 1
pubmed Jun 24, 2022

Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis.

Abroud. Hajer H; Beldi-Ferchiou. Asma A; Audard. Vincent V; Lemonnier. François F; Le Bras. Fab...

Scientists compared two lab tests that measure abnormal light‑chain proteins in the blood of people with a heart‑related amyloidosis. The newer ELISA test gave slightly lower numbers and was a bit less sensitive than the older nephelometry test, but both were good at spotting the disease (over 85% accuracy). The ELISA might be useful in tricky cases, but it isn’t a game‑changing tool for health‑hacking.

Utility 1
pubmed 2010

[Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging].

Kheĭfets. O V OV; Poliakova. V O VO; Kvetnoĭ. I M IM

A lab study found that short peptides called T-32, T-38, and cardiogen can boost certain proteins (CXCL12, WEDC1, ghrelin) in aging prostate fibroblast cells, even making their levels higher than in young cells. The effect was strongest for peptide T-38. The work is purely in cell culture and does not include human dosing or safety data.

pubmed Nov 28, 2017

[Experimental model for cardiogenic shock with pericardial tamponade].

Bari. Gábor G; Szűcs. Szilárd S; Érces. Dániel D; Ugocsai. Melinda M; Bozs...

Pericardial tamponade (PT) is a life-threatening condition, with low cardiac output. The hemodynamic consequences of PT can severely affect the circulation of all tissues, including the microcirculation of the kidneys and the intestinal mucosa. Our aim was to develop a hemodynamically stable and controllable large animal model of PT to study the consequences of cardiogenic shock. Two groups of anesthetized vietnamese minipigs (n = 6, both groups) were used. Following laparotomy, a cannula was fixed into the pericardium through the diaphragm without thoracotomy. A sham-operated group served as control, in the second group 60-min PT was induced by intrapericardial injection of heparinised own blood. Throughout PT and 180-min reperfusion, macrohemodynamics, renal circulation and mesenteric macro- and microcirculation were monitored. Myeloperoxidase (MPO) activity was measured and in vivo histology was performed by confocal laser scanning endomicroscopy. The PT increased central venous pressure, heart rate and decreased mean arterial pressure, mesenteric flow (from 355.5 ± 112.4 vs 182.0 ± 59.1 ml/min) and renal arterial flow (from 159.63 ± 50.7 vs 35.902 ± 27.9 ml/min) and the microcirculation of the ileum. Elevated MPO activity (3.66 ± 1.6 vs 7.01 ± 1.44 mU/mg protein) and injury of the ileal mucosa were present also. The reproducible large animal model is suitable for clinically relevant investigations of the hemodynamic and biochemical consequences of PT.

pubmed May 8, 2015

An Analysis of 3 Common CardioGen-82 82Rb Infusion System Injection Methods and Their Impact on Clinical Volume and Image Counts.

Roby. Amanda E AE; Johnson. Nils P NP; Gould. K Lance KL

The study compares three ways to inject the radioactive tracer used in heart PET scans and finds each method has trade‑offs in how much tracer is used, how much radiation the patient gets, and how clear the images are. It’s mainly about clinical imaging logistics, not about a peptide you can take for health or performance.

pubmed 2017

[Cardiomyopathy and ion channel diseases registry: the Szeged CardioGen Registry].

Blazsó. Péter P; Kákonyi. Kornél K; Forster. Tamás T; Sepp. Róbert R

The Szeged CardioGen Registry is a database that collects information on patients with various heart muscle diseases and electrical heart disorders. It mainly reports how many people have each condition and notes that the data for hypertrophic cardiomyopathy patients look similar to what other studies have found.